Interestingly, CMTM2, FOS, PIK3CB, SOS2, TLR4, IL18R1, CMTM6, and FPR1 were coregulated to regulate the SLE immune response, supporting the use of the biomarkers mentioned above in combination immunotherapy in future studies. The gene discussed is IL18R1; the disease is systemic lupus erythematosus.